QEL-001

N/A

Report date: 2026/02/25 20:02:36

Base Information

Drug NameQEL-001
Drug Alias NameQEL-001QEL-001 (antigen-specific CAR-Treg cell therapy)
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TregsCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsLiver FailureLiver DiseasesRejection of liver transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited KingdomSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesQuell Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQuell Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsLiver FailureLiver DiseasesRejection of liver transplantation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A